Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis

被引：0

作者：

Ikezawa, Yasuyuki ^{[1
,2
]}

Morita, Ryo ^{[3
]}

Mizugaki, Hidenori ^{[4
,5
]}

Tateishi, Kazunari ^{[6
]}

Yokoo, Keiki ^{[7
]}

Sumi, Toshiyuki ^{[8
]}

Kikuchi, Hajime ^{[9
]}

Kitamura, Yasuo ^{[10
]}

Nakamura, Atsushi ^{[11
]}

Kobayashi, Maki ^{[12
]}

Aso, Mari ^{[13
]}

Kimura, Nozomu ^{[14
]}

Yoshiike, Fumiaki ^{[15
]}

Megumi, Furuta ^{[2
]}

Tanaka, Hisashi ^{[16
]}

Sekikawa, Motoki ^{[17
]}

Hachiya, Tsutomu ^{[18
]}

Nakamura, Keiichi ^{[19
]}

Hommura, Fumihiro ^{[20
]}

Sukoh, Noriaki ^{[21
]}

Ito, Kenichiro ^{[22
]}

Kikuchi, Takashi ^{[23
]}

Agatsuma, Toshihiko ^{[24
]}

Yokouchi, Hiroshi ^{[4
]}

机构：

[1] Oji Gen Hosp, Dept Resp Med, Tomakomai, Japan

[2] Hokkaido Univ, Fac Med, Dept Resp Med, Sapporo, Japan

[3] Akita Kousei Med Ctr, Dept Resp Med, Akita, Japan

[4] Natl Hosp Org Hokkaido Canc Ctr, Dept Resp Med, 2-3-54,4jou,Shiroishi Ku, Sapporo, Hokkaido 0030804, Japan

[5] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Adv Med Dev, Tokyo, Japan

[6] Shinshu Univ, Sch Med, Dept Internal Med 1, Matsumoto, Japan

[7] Teine Keijinkai Hosp, Dept Resp Med, Sapporo, Japan

[8] Hakodate Goryoukaku Hosp, Dept Resp Med, Hakodate, Japan

[9] Obihiro Kousei Gen Hosp, Dept Resp Med, Obihiro, Japan

[10] Kushiro City Gen Hosp, Dept Resp Med, Kushiro, Japan

[11] Sendai Kousei Hosp, Dept Pulm Med, Sendai, Japan

[12] Miyagi Canc Ctr, Dept Resp Med, Natori, Japan

[13] Yamagata Prefectural Cent Hosp, Dept Resp Med, Yamagata, Japan

[14] Tohoku Univ, Grad Sch Med, Dept Resp Med, Sendai, Japan

[15] Nagano Municipal Hosp, Dept Resp Med, Nagano, Japan

[16] Hirosaki Univ, Grad Sch Med, Dept Resp Med, Hirosaki, Japan

[17] Steel Mem Muroran Hosp, Dept Resp Med, Muroran, Japan

[18] Japanese Red Cross Soc Suwa Hosp, Dept Resp Med, Suwa, Japan

[19] Natl Hosp Org Asahikawa Med Ctr, Dept Resp Med, Asahikawa, Japan

[20] Sapporo City Gen Hosp, Dept Resp Med, Sapporo, Japan

[21] Natl Hosp Org Hokkaido Med Ctr, Dept Resp Med, Sapporo, Japan

[22] KKR Sapporo Med Ctr, Dept Resp Med, Sapporo, Japan

[23] Iwate Prefecture Isawa Hosp, Dept Resp Med, Oshu, Japan

[24] Shinshu Ueda Med Ctr, Dept Resp Med, Ueda, Japan

来源：

CANCER MEDICINE | 2024年 / 13卷 / 14期

关键词：

chemotherapy; clinical cancer research; lung cancer; non-small cell lung cancer; CHEMOTHERAPY;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Selecting pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) for patients with nonsmall cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression is an important issue in clinical practice. We previously conducted a retrospective multicenter observational study of patients with NSCLC and high PD-L1 expression who received MONO or COMB as a first-line treatment. Here, we report updated data and evaluate the long-term outcomes. Methods: We performed a retrospective multicenter study of 298 patients with NSCLC and high PD-L1 expression who received MONO or COMB as first-line treatment between December 2018 and January 2020. We reviewed the medical records and assessed the clinical efficacy and toxicity using a prolonged data cutoff. Results: In total, 164 (median age: 74 years) and 134 (median age: 68 years) patients received MONO and COMB, respectively; patients who received COMB were younger and had better performance statuses (0-1). At the prolonged data cutoff, the median follow-up was 20.2 (range: 0.1-41.4) months. The median progression-free survivals were 7.5 and 13.1 months, and overall survivals (OSs) were 17.2 and 33.7 months for MONO and COMB, respectively. Treatment discontinuation rates were 21.9% and 20.1% for the MONO and COMB, respectively. With prolonged follow-up, although COMB demonstrated an OS benefit and higher objective response rate than MONO, in the propensity score matching analysis COMB didn't demonstrate a significant benefit compared to the MONO. Conclusions: COMB may be effective as a first-line treatment for NSCLC with high PD-L1 expression in a selected subset of patients.

引用

页数：11

共 15 条

[1]

Akinboro O, 2022, J CLIN ONCOL, V40

[2] Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study [J].

Chen, Ya ;

Wang, Yanan ;

Yang, Zhengyu ;

Hu, Minjuan ;

Zhang, Yanwei ;

Qian, Fangfei ;

Zhang, Wei ;

Zhang, Bo ;

Han, Baohui .

FRONTIERS IN ONCOLOGY, 2021, 11

[3] Pembrolizumab as a monotherapy or in combination with platinum-based chemotherapy in advanced non-small cell lung cancer with PD-L1 tumor proportion score (TPS) ≥50%: real-world data [J].

Dudnik, Elizabeth ;

Moskovitz, Mor ;

Rottenberg, Yakir ;

Lobachov, Anastasiya ;

Mandelboim, Rinat ;

Shochat, Tzippy ;

Urban, Damien ;

Wollner, Mira ;

Nechushtan, Hovav ;

Rotem, Ofer ;

Zer, Alona ;

Daher, Sameh ;

Bar, Jair .

ONCOIMMUNOLOGY, 2021, 10 (01)

[4] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].

Eisenhauer, E. A. ;

Therasse, P. ;

Bogaerts, J. ;

Schwartz, L. H. ;

Sargent, D. ;

Ford, R. ;

Dancey, J. ;

Arbuck, S. ;

Gwyther, S. ;

Mooney, M. ;

Rubinstein, L. ;

Shankar, L. ;

Dodd, L. ;

Kaplan, R. ;

Lacombe, D. ;

Verweij, J. .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247

[5] Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer [J].

Gadgeel, Shirish ;

Rodriguez-Abreu, Delvys ;

Speranza, Giovanna ;

Esteban, Emilio ;

Felip, Enriqueta ;

Domine, Manuel ;

Hui, Rina ;

Hochmair, Maximilian J. ;

Clingan, Philip ;

Powell, Steven F. ;

Cheng, Susanna Yee-Shan ;

Bischoff, Helge G. ;

Peled, Nir ;

Grossi, Francesco ;

Jennens, Ross R. ;

Reck, Martin ;

Garon, Edward B. ;

Novello, Silvia ;

Rubio-Viqueira, Belen ;

Boyer, Michael ;

Kurata, Takayasu ;

Gray, Jhanelle E. ;

Yang, Jing ;

Bas, Tuba ;

Pietanza, M. Catherine ;

Garassino, Marina C. .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) :1505-+

[6] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].

Gandhi, L. ;

Rodriguez-Abreu, D. ;

Gadgeel, S. ;

Esteban, E. ;

Felip, E. ;

De Angelis, F. ;

Domine, M. ;

Clingan, P. ;

Hochmair, M. J. ;

Powell, S. F. ;

Cheng, S. Y. -S. ;

Bischoff, H. G. ;

Peled, N. ;

Grossi, F. ;

Jennens, R. R. ;

Reck, M. ;

Hui, R. ;

Garon, E. B. ;

Boyer, M. ;

Rubio-Viqueira, B. ;

Novello, S. ;

Kurata, T. ;

Gray, J. E. ;

Vida, J. ;

Wei, Z. ;

Yang, J. ;

Raftopoulos, H. ;

Pietanza, M. C. ;

Garassino, M. C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092

[7] Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer [J].

Hong, Lingzhi ;

Aminu, Muhammad ;

Li, Shenduo ;

Lu, Xuetao ;

Petranovic, Milena ;

Saad, Maliazurina B. ;

Chen, Pingjun ;

Qin, Kang ;

Varghese, Susan ;

Rinsurongkawong, Waree ;

Rinsurongkawong, Vadeerat ;

Spelman, Amy ;

Elamin, Yasir Y. ;

Negrao, Marcelo V. ;

Skoulidis, Ferdinandos ;

Gay, Carl M. ;

Cascone, Tina ;

Gandhi, Saumil J. ;

Lin, Steven H. ;

Lee, Percy P. ;

Carter, Brett W. ;

Wu, Carol C. ;

Antonoff, Mara B. ;

Sepesi, Boris ;

Lewis, Jeff ;

Gibbons, Don L. ;

Vaporciyan, Ara A. ;

Le, Xiuning ;

Jack Lee, J. ;

Roy-Chowdhuri, Sinchita ;

Routbort, Mark J. ;

Gainor, Justin F. ;

Heymach, John V. ;

Lou, Yanyan ;

Wu, Jia ;

Zhang, Jianjun ;

Vokes, Natalie I. .

NATURE COMMUNICATIONS, 2023, 14 (01)

[8] Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression [J].

Ikezawa, Yasuyuki ;

Mizugaki, Hidenori ;

Morita, Ryo ;

Tateishi, Kazunari ;

Yokoo, Keiki ;

Sumi, Toshiyuki ;

Kikuchi, Hajime ;

Kitamura, Yasuo ;

Nakamura, Atsushi ;

Kobayashi, Maki ;

Aso, Mari ;

Kimura, Nozomu ;

Yoshiike, Fumiaki ;

Furuta, Megumi ;

Tanaka, Hisashi ;

Sekikawa, Motoki ;

Hachiya, Tsutomu ;

Nakamura, Keiichi ;

Shimokawa, Mototsugu ;

Oizumi, Satoshi .

CANCER SCIENCE, 2022, 113 (06) :2109-2117

[9] Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial [J].

Mok, Tony S. K. ;

Wu, Yi-Long ;

Kudaba, Iveta ;

Kowalski, Dariusz M. ;

Cho, Byoung Chul ;

Turna, Hande Z. ;

Castro, Gilberto, Jr. ;

Srimuninnimit, Vichien ;

Laktionov, Konstantin K. ;

Bondarenko, Igor ;

Kubota, Kaoru ;

Lubiniecki, Gregory M. ;

Zhang, Jin ;

Kush, Debra ;

Lopes, Gilberto .

LANCET, 2019, 393 (10183) :1819-1830

[10] Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer [J].

Paz-Ares, L. ;

Luft, A. ;

Vicente, D. ;

Tafreshi, A. ;

Gumus, M. ;

Mazieres, J. ;

Hermes, B. ;

Senler, F. Cay ;

Csoszi, T. ;

Fulop, A. ;

Rodriguez-Cid, J. ;

Wilson, J. ;

Sugawara, S. ;

Kato, T. ;

Lee, K. H. ;

Cheng, Y. ;

Novello, S. ;

Halmos, B. ;

Li, X. ;

Lubiniecki, G. M. ;

Piperdi, B. ;

Kowalski, D. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2040-2051

← 1 2 →